在肥胖和2型糖尿病中准英克雷丁系统
Saleem Ansari1, Bernard Khoo2, Tricia Tan3
1Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
基于因克雷丁的疗法,如葡萄糖样1受体激动剂 (GLP1RAs),正在针对肥胖和2型糖尿病 (T2DM) 取得进展. 新的组合疗法和口服选择为心血管疾病和代谢障碍提供了改善的治疗潜力.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖和2型糖尿病 (T2DM) 是全球主要的健康挑战,往往导致心血管疾病 (CVD).
- 生活方式的改变和代谢手术在解决这些广泛的疾病方面存在局限性.
- 基于因克雷丁的疗法,特别是类似葡萄糖的1受体激活剂 (GLP1RAs),已成为T2DM和肥胖症的关键治疗方法,具有新兴的CVD益处.
研究的目的:
- 审查最近在肥胖和T2DM的基于因克雷丁的药物治疗方面取得的进展.
- 突出新的治疗策略,包括组合疗法和口服配方.
- 讨论这些进展对管理相关心血管风险的潜在影响.
主要方法:
- 审查当前的科学文献和临床证据,以英克雷为基础的疗法.
- 分析新兴的"GLP1加"药物,将GLP1RA活性与其他激素结合起来.
- 第二代非性口服GLP1RAs的评估.
主要成果:
- GLP1RAs是治疗肥胖和T2DM的基石,证明了对心血管的好处.
- "GLP1 plus"药物整合了多种激素作用,以改善治疗结果.
- 口服GLP1RA正在开发中,以改善患者的坚持和可访问性.
结论:
- 基于因克雷的药物治疗继续发展,为肥胖和T2DM提供更有效的治疗选择.
- 组合疗法和口服配方在治疗这些代谢疾病及其并发症方面取得了重大进展.
- 需要进一步的研究来优化这些先进疗法的部署,以获得最大的患者益处.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
